The introduction of lenacapavir into the Mozambican health system marks a new chapter in the national response to the Human Immunodeficiency Virus (HIV), bringing to the field a preventive technology that combines clinical efficacy with ease of use.
With just two annual administrations, the drug emerges as a strategic alternative to reduce the number of new infections, especially among adolescents and young people—a group that continues to account for a significant portion of the cases registered in the country.
The first dose was administered at a time that symbolizes the launch of a drug representing a paradigm shift in how prevention is conceived and applied. Instead of relying exclusively on daily adherence to pills, the new model focuses on a long-term approach, capable of responding to the real challenges faced by at-risk populations.
The country registers approximately 92,000 new infections annually, with more than a third occurring among young people aged 15 to 24. It is precisely in this segment that lenacapavir could have the greatest impact, offering a discreet, effective solution that is less dependent on rigorous routines—factors that often compromise adherence to conventional prevention strategies.
The new approach falls under the Pre-Exposure Prophylaxis model and is intended for people who test negative for the virus. In an initial phase, the medication will be available in 55 health units, covering the provinces of Maputo and Zambézia, with the prospect of gradual expansion.
Beyond the clinical impact, there is also a relevant social dimension. Authorities believe that the injectable format could help reduce the stigma still associated with HIV prevention, creating conditions for greater adherence, especially among young people who avoid health services for fear of discrimination.
The implementation has the support of international partners, such as the World Health Organization and the United States Government, reinforcing the global nature of the response to the epidemic. For these institutions, the arrival of lenacapavir represents a significant advance, with the potential to alter the course of the disease in high-incidence contexts.
(By Rafael Langa)
